Plus   Neg

Tenax Therapeutics' Phase II Pulmonary Hypertension Trial Produces Mixed Results

Tenax Therapeutics Inc.'s (TENX) phase II trial, which evaluated Levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction, has produced mixed results.

In the study, dubbed HELP, the primary endpoint of the change from baseline Pulmonary capillary wedge pressure (PCWP) with bicycle exercise (25Watts) at week 6 following five weekly infusions of Levosimendan post-randomization did not demonstrate a statistically significant reduction from baseline.

However, Levosimendan did demonstrate a statistically significant reduction in PCWP compared to baseline and placebo when the measurements at rest, with legs up and on exercise, were combined, the Company noted.

The trial also demonstrated a statistically significant improvement in 6-minute walk distance of 29 meters, which was the secondary endpoint - a validated and accepted endpoint in many pulmonary hypertension registration trials.

TENX closed Monday's trading at $1.45, up 0.69%.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT